Advertisement
BioTrends has been following Feraheme in its TreatmentTrends(R): US Nephrology reports since the end of 2006. According to the most recent TreatmentTrends(R) survey, interest in the product is high, particularly in the CKD-ND setting, although Nephrologists predict uptake across all patient types.
Advertisement
LaunchTrends(TM) measure launch effectiveness of new products from FDA approval through six months post launch. The first wave of the LaunchTrends(TM): Feraheme report series will be fielded in mid-August, measuring uptake at one month. Topline findings will be available shortly thereafter and the full report will follow in mid-September.
About BioTrends Research Group, Inc.
BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. To purchase this report or to learn more about BioTrends' syndicated publications, please contact us at (610) 363-3872 or visit us at www.bio-trends.com.
All company, brand, or product names contained in this document may be trademarks of their respective holders.
SOURCE BioTrends Research Group, Inc.